Nonthyroidal illness syndrome (NTIS) affects patients with myocardial infarction (MI). Oxidative stress has been implicated as a causative factor of NTIS, and reversed via N-acetylcysteine (NAC). Male Wistar rats submitted to left anterior coronary artery occlusion received NAC or placebo. Decreases in triiodothyronine (T3) levels were noted in MI-placebo at 10 and 28 days post-MI, but not in MI-NAC. Groups exhibited similar infarct areas whereas MI-NAC exhibited higher ejection fraction than did MI-placebo. Left ventricular systolic and diastolic diameters were also preserved in MI-NAC, but not in MI-placebo. Ejection fraction was positively correlated with T3 levels. Oxidative balance was deranged only in MI-placebo animals. Increased type 3 iodothyronine deiodinase expression was detected in the cardiomyocytes of MI-placebo compared with normal heart tissue. NAC was shown to diminish type 3 iodothyronine deiodinase expression and activity in MI-NAC. These results show that restoring redox balance by NAC treatment prevents NTIS-related thyroid hormone derangement and preserves heart function in rats subjected to MI. (Endocrinology 158: 1502(Endocrinology 158: -1510(Endocrinology 158: , 2017 
T hyroid hormones are essential for growth, development, and metabolism in virtually every body system. Thyroid hormone homeostasis is critically regulated by the synchronized activities of the iodothyronine deiodinases. Type 1 (D1) and type 2 iodothyronine deiodinases catalyze the conversion of the prohormone thyroxine (T4) into the biologically active triiodothyronine (T3) via outer ring deiodination. In contrast, type 3 iodothyronine deiodinase (D3) catalyzes the inactivation of T4 and T3 via inner-ring deiodination (1) .
The metabolic signature of the nonthyroidal illness syndrome (NTIS), also known as low T3 syndrome, is the thyroid hormone level alterations that occur in almost every form of acute or chronic illness (2) . The pathophysiology of NTIS is complex. It was recently shown in a cell culture system that changes in intracellular redox balance alter T3/T4 activation/inactivation during the acute phase of the disease (3) . Increased reactive oxygen species (ROS) generation reduces D1 and type 2 iodothyronine deiodinase function while increasing D3 function, resulting in decreased serum T3 levels and increased reverse T3 (rT3) concentrations. These alterations can be prevented by N-acetylcysteine (NAC), an antioxidant that raises intracellular cysteine levels and corrects glutathione (GSH) levels, restoring redox equilibrium. Neuroendocrine abnormalities seem to predominate in the setting of prolonged disease, and a reduced thyrotropin (TSH) level seems to be the most frequently observed abnormality in this setting (4, 5) . Interestingly, studies utilizing postmortem samples have shown that D3 expression is induced in several tissues in disease state, further implicating this enzyme in illnessrelated thyroid hormone derangements (6) (7) (8) (9) .
NTIS is commonly observed in patients with myocardial infarction (MI) (10, 11) . Low T3 levels are an independent marker of myocardial damage and are associated with a poor prognosis (12) (13) (14) . The impact of T3 levels on heart disease can be explained by the physiological actions of the hormone (15) (16) (17) . Thyroid hormone activity in the cardiomyocyte regulates myocardial contractility, diastolic and systolic function. T3 activates and regulates cardiac genes encoding proteins such as the myosin heavy chain isoforms and the sarcoplasmic reticulum calcium-activated adenosine triphosphatase pump. Thus, thyroid hormones exert profound effects on the heart and on cardiovascular hemodynamics, maintaining cardiac mass and wall stress while preserving ellipsoid left ventricular geometry (16) . Thyroid hormones also have a direct inotropic effect on the heart through both genomic and nongenomic effects on components of the adrenergic receptor complex and on sodium, potassium, and calcium channels. Thyroid hormone metabolism is reportedly abnormal in acute heart disease, as well as in the setting of cardiac hypertrophy and heart failure (15) (16) (17) .
We recently showed that NAC administration prevents the thyroid hormone derangements that commonly occur in patients during the acute phase of MI (18) . In this study, we aimed to determine whether attenuating decreases in serum T3 levels impacts MI-related cardiac dysfunction in an animal model of NTIS (15) . Additionally, we explored the physiopathological role of cardiomyocyte D3 expression in heart function alterations.
Materials and Methods

Reagents
Reagents were obtained from Invitrogen (Life Technologies, Grand Island, NY), Calbiochem-Novabiochem (St. Louis, MO), or Sigma-Aldrich (St. Louis, MO).
Animals and procedures
Male Wistar rats (weighing 6 250 g) were used in the experiments. All procedures and experiments involving animals were performed in accordance with the recommendations of the Brazilian College of Animal Experimentation. Our study complied with the ethical principles of the Guide for the Care and Use of Laboratory Animals (19) and the international standards for animal research of the Guidelines for Reporting Animal Research (20) . This study was approved by the Research Ethics Committee of our institution (protocol 130501). All animals received standard food and water ad libitum and were kept in cages under 12-hour light/dark cycles.
On the day of MI induction, the animals underwent basal echocardiography and blood sample collection (retro-orbital plexus) before being subjected to anterior descending artery ligation, as previously described (21, 22) , resulting in infarction of the left ventricle (LV) free wall. Briefly, the rats were anesthetized intraperitoneally (1 mL/kg ketamine and 0.5 mL/kg xylazine), intubated, and connected to a mechanical ventilator with ambient air at a volume of 2.5 mL and ventilatory rate of 65 breaths per minute using a pressure fan for rodents (Harvard Apparatus, Holliston, MA, model 683). Anesthesia was administered through a vaporizer (Surgivet, St. Louis, MN) containing isoflurane (1 mL/mL; Isoforine; Cristália, Itapira, SP, Brazil). After MI or sham procedure, tramadol (20 mg/kg, every 6 hours for 48 hours, Teuto, Anápolis, GO, Brazil) was administered and animals were kept under medical oxygen at temperatures of 25 to 27°C for 6 hours. Twelve hours after surgery, blood was collected for troponin measurements to confirm successful MI induction. The animals were then divided into two groups (10 or 28 days of follow-up) and randomly assigned to receive either intraperitoneal NAC (10 mg/kg, 12-hour light/dark cycle for 48 hours, n = 20) or the same volume of vehicle (saline, n = 20; placebo group). Serial cardiac functional assessments and measurements of serum TSH, T4, T3, and rT3 levels were performed on the day of the procedure and at 10 or 28 days after surgery. Previous publications showed that neither T3 levels nor echocardiographic parameters changed at 28 days post-MI (23, 24) .
At the conclusion of each experimental period (10 or 28 days), the animals were euthanized [anesthetized with a vaporizer (Surgivet) containing isoflurane and decapitated with a guillotine] and tissues were rapidly removed and frozen in liquid nitrogen before being stored for subsequent analyses. Hearts were separated into LV infarcted tissue, LV noninfarcted tissue, and non-LV noninfarcted heart tissue. For each sample, before dissection, one portion of the heart was fixed in 4% paraformaldehyde and processed for immunohistochemistry. The noninfarcted areas used for experiments were selected from remote nonaffected LV tissue.
Echocardiography
Echocardiograms were performed before MI and at 48 hours and 10 or 28 days post-MI. Animals were anesthetized with 2.5% isoflurane (in 0.5 L/min O 2 ) via inhalation and placed in the left lateral decubitus position (45°) so that we could obtain parasternal and apical cardiac images. An EnVisor HD system by Philips Medical (Andover, MA) and a 12-3 MHz transducer, 2 cm deep, were used, as was fundamental harmonic imaging (25) . All echocardiographic analyses were performed by the same blinded echocardiographer. Anterior and posterior enddiastolic and end-systolic wall thickness and relative wall thickness were measured. Systolic function was expressed as the ejection fraction (EF), which was calculated using Simpson's method.
Plasma thyroid hormone, troponin, and carbonyl measurements
Measurements of T3, T4, rT3, TSH, and troponin levels were performed via electrochemiluminescence immunoassay (Siemens ADVIA Centaur XP). The interassay coefficients of variation were as follows: T3, 7.1%; T4, 10%; FT4, 7%; and rT3, ,10%. The intra-assay coefficients of variation were as follows: T3, 6.2% to 7%; T4, 3% to 8%; FT4, 3% to 6%; and rT3, 6% to 8%. For carbonyl measurements, duplicate aliquots of plasma (containing ;0.3 mg of protein) from each sample were incubated with 500 mL of 10 mM 2,4-dinitrophenylhydrazine or 1.0 mL of 2 M HCl (blank tube). After 30 minutes, 250 mL of 50% trichloroacetic acid was added to the aliquots. The samples were subsequently centrifuged at 8000g for 30 minutes to obtain the protein pellets, which were immediately washed with ethanol/ethyl acetate at a 1:1 volume-to-volume ratio (v/v). The final protein pellets were diluted in 500 mL of 8 M urea buffer and incubated at 50°C for 90 minutes. The difference between the 2,4-dinitrophenylhydrazine treated and HCl-treated samples (blank) was used to calculate the carbonyl content determined at 370 nm. The carbonyl content was calculated using the millimolar absorption coefficient of hydrazine (e370 nm = 2.1 3 10 4 M 21 cm
21
), and the results were expressed as nanomoles carbonyl per milligram protein and evaluated by the Bradford method.
Determination of tissue protein carbonyl content
Duplicate aliquots of 0.3 mg of protein homogenate of each tissue type were incubated with 500 mL of 10 mM 2,4-dinitrophenylhydrazine or 1.0 mL of 2 M HCl (blank tube). After 30 minutes, 250 mL 50% trichloroacetic acid was added to the aliquots. The samples were subsequently centrifuged at 8000g for 30 minutes to obtain the protein pellets, which were immediately washed with ethanol/ethyl acetate at 1:1 (v/v). The final protein pellets were resuspended in 500 mL of 8 M urea buffer and incubated at 50°C for 90 minutes. The difference between the 2,4-dinitrophenylhydrazine-treated and HCltreated samples (blank) was used to calculate the carbonyl content determined at 370 nm. Carbonyl content was calculated using the millimolar absorption coefficient of hydrazine (e370 nm = 2.1 3 10 4 M 21 cm
21
), and the results were expressed in nanomoles carbonyl per milligram of protein (26) .
Nonenzymatic antioxidant defenses
Reduced GSH levels were measured according to a standard method. Briefly, tissues were homogenized in the presence of 300 mL of 20 mM sodium phosphate and 140 mM KCl buffer (pH 7.4). Proteins were precipitated by adding sodium metaphosphoric acid for a final ratio of 1:1. Samples were centrifuged for 10 minutes at 7000g. Fifteen microliters of tissue preparation was incubated with an equal volume of o-phthaldialdehyde (1 mg/mL methanol) at room temperature for 15 minutes in the presence of 20 volumes (1:20 v/v) of 100 mM sodium phosphate buffer (pH 8.0) containing 5 mM EDTA. Fluorescence was measured using excitation and emission wavelengths of 350 nm and 420 nm, respectively. A calibration curve was generated using standard GSH (0.001 to 0.1 mM), and GSH concentrations were calculated as nanomoles per milligram protein. Total GSH and oxidized GSH (GSSG) levels were determined using the enzymatic recycling method described by Teare et al. (27) , with some modifications. Briefly, tissues were homogenized in 4 volumes of a sulfosalicylic acid solution (11%) and Triton X-100 (0.11%) (1:1 weight-to-volume ratio). After incubating for 5 minutes at 4°C with continuous shaking, the samples were centrifuged at 10,000g for 10 minutes (4°C), and the supernatant was collected for analyses of glutathione levels. For GSSG measurement, 10 mL of the supernatant was added to 110 mL of a GSH masking buffer [100 mM phosphate buffer, 1 mM EDTA, 1.1% 2-vinylpyridine (pH 7.4)] and incubated for 1 hour at room temperature. The samples prepared for total GSH and GSSG measurement were subjected to enzymatic analysis in a recycling buffer system containing 300 mM reduced form of NAD phosphate, 225 mM 5 0 ,5 0 -dithio-bis(2-nitrobenzoic acid), 1.6 U/mL glutathione reductase, and 1.0 mM EDTA in 100 mM phosphate buffer (pH 7.4). The linear increase in absorbance at 405 nm over time was monitored using a microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA). A standard curve was generated using known amounts of GSH (100 mM) and GSSG (3.47, 6.95, and 13.89 mM).
D3 activity assay
D3 activity in tissue samples was determined using paper chromatography as previously described (3, 28) . Tissues were Serum rT3 levels were augmented in the placebo group at 10 days but stable in NAC-treated rats. The T3/rT3 ratio is progressively augmented in NAC-treated animals whereas it diminishes in the placebo group until day 10 (c). *P , 0.001, n = 20 in each group.
individually homogenized and sonicated with 10 mM Tris-HCl, 0.25 sucrose buffer (pH 7.5), and 10 mM dithiothreitol. Protein concentration was quantified by Bradford assay using bovine serum albumin as a standard. The homogenates were incubated for 1 hour with 200,000 counts per minute 125 I-labeled T3, 2 nM T3, 20 mM dithiothreitol, and 1 mM propylthiouracil to inhibit any D1 activity. The addition of 200 nM of T3 completely abolished D3 activity in all samples. The reaction was stopped by adding 200 mL of ethanol (95%), 50 mL of NaOH (0.04 N), and 5 mg propylthiouracil. Deiodination was determined based on the amount of 125 I-3,5-diiodothyronine (T2) produced after separation of reaction products by paper chromatography. Results were expressed as the fraction of T2 counts minus the nonspecific deiodination (always ,1.5%), obtained with the saturating concentration of T3 (200 nM). D3 activity was expressed as fentomoles T3 per minute per milligram of protein. The quantity of protein assayed was adjusted to ensure that ,30% of the substrate was consumed. All experiments were performed in triplicate in at least two independent experiments.
Immunohistochemistry
D3 expression was evaluated via immunohistochemistry in matched normal and peri-infarcted tissue samples from placebo and NAC-treated rats. Heart tissue samples from animals subjected to surgery without artery ligation were used as controls (sham group, n = 20). D3 expression analysis was performed using 6-mm sections of formalin-fixed and paraffinembedded tissues. The immunohistochemistry technique included tissue deparaffinization and rehydration, antigenic recovery, endogenous peroxidase inactivation, and unspecific reaction blockage. The samples were incubated with D3 antirabbit polyclonal antibodies (Novus Biologicals, Littleton, CO) overnight at 4°C at a dilution of 1:300 (the same antibody concentration was used for the positive-control samples), followed by incubation with biotinylated streptavidin/ horseradish peroxidase-conjugated secondary antibodies (LSAB kit; Dako, Carpinteria, CA) and diaminobenzidine tetrahydrochloride (DAB kit; Dako). Placental tissue samples served as positive controls. Normal lung tissue was used as negative-control samples. Slides were examined using an Olympus BX51 microscope with an Olympus QColor 5 camera, and QCapturePro software was used to capture the images.
Statistical analysis
Unless otherwise specified, the results are presented as the mean 6 standard deviation. Data were analyzed using a twotailed Student t tests or one-way analysis of variance followed by post hoc Duncan multiple range tests when F was significant. Linear regression analysis was also used to verify concentrationdependent effects. Prism 6.0 software was used for statistical analyses, and P , 0.05 was considered significant.
Results
Animal model of MI and NTIS
Compared with baseline, serum T3 levels were decreased in MI-placebo animals at 10 (108 to 88.4 ng/dL; P , 0.01) and 28 days (108.5 to 91.6 ng/dL; P , 0.03) post-MI. In contrast, no significant decreases in T3 levels were noted in MI-NAC animals at 10 or 28 days post-MI (107 to 97.3 ng/dL, P = 0.8; 107 to 100 ng/dL, P = 0.8, respectively) [ Fig. 1(a) ]. No significant differences in serum T4 levels were observed between the two groups [5.49 6 0.3 vs 5.5 6 0.22 mg/dL; P = 0.77; Fig. 1(b)] . The baseline rT3 level was 11.2 6 0.4 ng/dL in the MIplacebo group and increased to 14 6 0.6 ng/dL at 10 days post-MI [P = 0.0001, Fig. 1(c) ]. No significant changes in rT3 levels were observed in the MI-NAC group (11.2 6 0.4 vs 11 6 0.4 vs 11.4 6 0.9 ng/dL at baseline and 10 and 28 days post-MI, respectively; P = 0.8). Interestingly, whereas the T3/rT3 ratio remained low and stable in the placebo group [8.7 to 7.4 to 7.75 at baseline and 10 and 28 days post-MI, respectively; P = 0.6; Fig. 1(d)] , it increased over time in the MI-NAC group [8.7 to 9.6 to 9.1 at baseline and 10 and 28 days post-MI, respectively; P = 0.002; Fig. 1(d) ]. Serum TSH levels were virtually identical between the two groups (1.03 vs 1.12 ng/mL; P = 0.8).
Antioxidant treatment prevents thyroid hormone derangements and ameliorates MI-induced cardiac abnormalities
The placebo and NAC groups exhibited similar baseline echocardiographic measurements (Fig. 2) . Twelve hours post-MI, both groups exhibited comparable infarcted area extensions as measured by echocardiography (;50%). Accordingly, troponin levels (46 vs 43 ng/L; P = 0.7) and heart rates were similar between the two groups (P = 0.43). The infarct size (expressed as a ratio of the percentage of infarcted area to total LV mass) at the time of euthanasia did not differ between the groups at 10 (40.3 6 1.1 vs 39.6 6 1.3, P = 0.7) and 28 (43.1 6 1.5 vs 38.9 6 2.5, P = 0.2) days. Heart weight was increased in the MI-placebo group (1.08 6 0.06 vs 1.3 6 0.3 vs 1.4 6 0.05 g at baseline and 10 and 28 days post-MI, respectively; P = 0.03), in this case most likely due to hypertrophy and remodeling and was unchanged in the MI-NAC group (1.08 6 0.06 vs 1.12 6 0.06 vs 1.17 6 0.1 g at baseline and 10 and 28 days post-MI, respectively; P . 0.05).
The EF was ;22% higher in MI-NAC animals than in MI-placebo animals at 10 (72 vs 57.3%; P , 0.001) and 28 days post-MI [72.3 vs 56%; P , 0.001; Fig. 2(a) ]. The improvement of diastolic function was also evidenced by the lower earlyto-late ratio of ventricular filling velocities in IM-NAC animals as compared with IAM-placebo (2 vs 2.6, P = 0.005 at 10 days; 2.1 vs 2.5, P = 0.001 at 28 days).
Next, we sought to evaluate whether serum T3 levels correlate with heart function parameters. Interestingly, the EF was positively correlated with T3 levels at 10 [r = 0.85, P , 0.0001, Fig. 3(a) ] and 28 [r = 0.7, P = 0.0001, Fig.  3(b) ] days post-MI.
NAC administration restores total carbonyl content and nonenzymatic antioxidant compounds
Total carbonyl content, a parameter of protein oxidation, was subsequently measured. Plasma carbonyl content increased during the initial hours post-MI (data not shown) and was higher in both the MI-placebo group and the MI-NAC group than in the sham group at 10 [P , 0.002, Fig. 4(a) ] and 28 days post-MI [P = 0.01, Fig.  4(a) ]. Peri-infarcted heart tissue samples exhibited increased carbonyl content in the MI-placebo group compared with the MI-NAC group at 10 [P = 0.0001, Fig. 4(b) ] and 28 days post-MI [P = 0.01, Fig. 4(a) ]. Noninfarcted heart tissue samples also exhibited increased carbonyl content in the MI-placebo group at 10 [P = 0.004, Fig. 4(c) ] and 28 days post-MI [P = 0.01, Fig. 4(c) ].
We then determined the concentrations of the nonenzymatic antioxidant GSH in all tissues. GSH content was diminished in the peri-infarcted tissue samples of MI-placebo animals, but not MI-NAC animals, at 10 [P , 0.001, Fig. 5 
D3 expression and activity in cardiomyocytes is affected by NAC
We subsequently determined the role of D3 expression in myocardial tissue damage. D3 protein expression levels were determined via immunohistochemistry and enzyme assay activity. We observed an increased D3 staining (fourfold) in peri-infarcted myocardial tissue of the MIplacebo group compared with sham tissue [P , 0.001, Fig. 6(a) ]. However, D3 staining levels in the periinfarcted samples of MI-NAC animals were not different from those in the tissue samples of sham animals [P . 0.05, Fig. 6(a) ]. Accordingly, D3 activity levels were augmented at 10 and 28 days post-MI in the peri-infarcted tissue samples of the placebo group when compared with sham [7.4 6 0.6 vs 5.22 6 0.5 vs 2.18 6 0.4 fmol/mg protein/min, respectively, P , 0.0001, Fig. 6(b) ]. Interestingly, D3 activity in the periinfarcted tissue of MI-NAC animals was not different from sham animals [4.6 6 0.4 vs 3.7 6 0.6 vs 2.18 6 0.4 fmol/mg protein/min, respectively, P . 0.05, Fig. 6(b) ].
Discussion
The present study was designed to investigate whether attenuating oxidative stress impacts NTIS and heart function in rats subjected to MI. We showed that NAC treatment prevents decreases in T3 levels and preserves heart function. Accordingly, the EF was shown to be strongly correlated with serum T3 levels. MI was associated with altered redox balance and increased D3 levels in infarcted heart tissue samples. Taken together, these findings indicate that a correlation exists among oxidative stress-induced thyroid hormone inactivation, low T3 levels, and altered heart function in MI-related NTIS.
NTIS is characterized by several changes in thyroid hormone physiology, the most striking of which are decreases in T3 levels and increases in rT3 levels, which are observed in a variety of illnesses. NTIS is commonly observed in patients suffering from MI, and low serum T3 levels are inversely correlated with mortality (12) . Previous studies have noted improvements in cardiac systolic and diastolic function, as well as subsequent improvements in hemodynamics and myocardial perfusion, in patients treated with thyroid hormones (15, 29, 30) . Accordingly, authors have attempted to restore serum T3 levels or T3-related gene expression in rat models of MI and low T3 syndrome by administering high doses of T3 or T4 (15, 29, 30) . This approach has been shown to increase the EF by ;10% and to improve ventricular function but has not been shown to have any effect on left or right ventriclular mass or cardiac hypertrophy (15, 30) . To date, all attempts to treat NTIS have involved administering thyroid hormone replacement therapy. In this study, confirming previous studies performed in cell culture systems and MI patients, we demonstrated that NAC administration attenuates MI-induced oxidative stress and prevent the characteristic changes in serum thyroid hormone levels as observed in NTIS. This indicates that thyroid hormone derangement occurs mainly as a result of changes in redox balance affecting peripheral thyroid hormone metabolism (3, 18) . NACtreated animals exhibited higher EF and better preserved LV systolic and diastolic diameters compared with placebo-treated group (Fig. 2) . Consistently, we observed a positive correlation between plasma T3 levels and the EF (Fig. 3) . Nevertheless, we cannot exclude an associated NAC-related beneficial effect on heart function. These results demonstrate that NAC attenuates Figure 4 . Oxidative stress biomarkers in rats subjected to MI that received NAC or placebo. (a) A significant augmentation in total plasma carbonyl content was observed in the placebo group, whereas total carbonyl content decreased significantly and reached the levels observed in sham in NAC-treated group. Total tissue carbonyl content was increased in the peri-infarcted (b) and noninfarcted heart tissue samples of the placebo group (c). *P , 0.001, n = 20 in each group.
MI-related NTIS and results in myocardial protection.
The data presented in this study have provided us with new insights regarding the pathophysiology of NTIS-associated thyroid hormone level changes and heart function.
Changes in redox balance are known to disrupt deiodinase function (31) . Increases in ROS induce D3, an oxidoreductase that catalyzes iodine removal from the inner rings of thyroid hormones, inactivating them (1). The role of D3 has been implicated in NTIS by experimental and clinical studies (7) (8) (9) 32) . Interestingly, it was recently shown that patients with low T3 syndrome secondary to postoperative atrial fibrillation presented with elevated T2 levels. Systemic D3 upregulation diminishes T3 levels but increases those of T2, further explaining why these patients do not benefit from exogenous thyroid hormone administration (33) . ROSinduced D3 upregulation can be fully corrected by the antioxidant NAC, a thiol-containing radical scavenger and glutathione precursor (3, 34, 35) . Although the effect of NAC on D3 expression and activity is still not fully understood, it is probably associated with the maintenance of intracellular GSH levels, as well as the correction of redox imbalance (Figs. 4 and 5) . Interestingly, GSH has the unusual property that it becomes a more potent reductant and effective antioxidant as its concentration increases, as a consequence of the formation of disulfide bridges between two GSHs. Therefore, modest increases in GSH concentration result in exceptionally large effects on the antioxidant network. Thus, one can suppose that rather than increasing GSH levels, NAC administration immediately after the MI prevents a decrease in GSH levels, as observed in the placebo group. Elegant studies have shown that cardiomyocyte D3 induction post-MI is associated with a 50% reduction of tissue T3 levels, leading to a local hypothyroid condition and affecting LV remodeling (16) . Thus, we decided to also investigate the effect of NAC treatment on heart D3 expression and activity. We show that cardiomyocyte D3 expression is increased in peri-infarcted tissue in the placebo-MI group but not in NAC-treated animals (Fig. 6) , suggesting that the preservation of heart function is dependent on the maintenance of intracellular thyroid hormone levels by NAC administration. Interestingly, D3 immunostaining and activity showed similar results, suggesting that protein and activity levels correlate in heart tissue.
Taken together, our findings demonstrate that improvement of the MI-related redox imbalance by NAC prevents the abnormalities in thyroid hormone metabolism and improves cardiac performance. Moreover, Figure 5 . GSH levels were diminished in both the peri-infarcted (a) and in the noninfarcted (b) heart tissue of the placebo group, but not the NAC-treated animals. The GSH/GSSG ratio was shown to be reduced in the placebo group in both peri-infarcted (c) and noninfarcted (d) heart tissue. *P , 0.001, n = 20 in each group.
our results confirm that tissue D3 induction likely contributes to the cardiac injury associated with ischemic heart disease. Whether antioxidants such as NAC could be beneficial as an adjuvant therapy in MI patients, as well as its putative impact on patient survival, remains to be evaluated.
